Understanding and Treating Glioblastoma

Area of Science:

• Oncology
• Medical Physics

Background:

• Standard treatments for newly diagnosed patients have seen little advancement in ten years.
• Previous concept-driven therapies, including anti-angiogenic and molecularly targeted drugs, have not succeeded in broad patient populations.
• Tumor-treating fields (TTFields) represent a novel therapeutic modality.

Purpose of the Study:

• To explore TTFields as a new treatment option for newly diagnosed patients.
• To highlight the limitations of current precision medicine trials focusing on the newly diagnosed population.
• To address the lack of established standards and the ineffectiveness of treatments at disease progression.

Main Methods:

• Review of current treatment paradigms for newly diagnosed patients.
• Analysis of the failure of 'all-comers' approaches in clinical trials.
• Emphasis on the need for molecular precision and analysis of recent tumor tissue for patients at progression.

Main Results:

• TTFields emerge as a promising alternative for newly diagnosed patients.
• Current immunotherapy and molecularly targeted trials are primarily focused on the newly diagnosed population.
• No standard treatment exists for patients at progression, with limited options beyond supportive care.

Conclusions:

• Molecular precision approaches are crucial for treating patients at progression.
• Recent tumor tissue analysis is essential for effective precision medicine at progression.
• Future research should focus on targeted strategies rather than broad 'all-comers' approaches, especially at disease progression.